statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biofrontera Inc. (NASDAQ:BFRI - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 84,200...

Biofrontera Inc. (NASDAQ:BFRI) Sees Significant Decline in Short Interest

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatological products, today...

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

Q4 2023 Biofrontera Inc Earnings Call Transcript

(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call begins at 10:00 a.m. Eastern time on Monday, March 18...

CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company...

Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update

WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will...

Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024

Biofrontera Inc. (NASDAQ:BFRI  Free Report)  Analysts at Roth Capital issued their FY2028 earnings estimates for shares of Biofrontera in a research note issued to investors on...

Biofrontera Inc. to Post FY2028 Earnings of $3.62 Per Share, Roth Capital Forecasts (NASDAQ:BFRI)

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rulesFunding and...

Biofrontera Inc. Announces Closing of Private Placement of up to $16.0 Million Priced at Market per Nasdaq Rules

Biofrontera announced it has entered into a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors. Pursuant to the securities purchase agreements, the...

What's Going On With Biofrontera Stock?

Ameluz (R) transfer price to Biofrontera AG reduced significantlyControl of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1WOBURN, MA / ACCESSWIRE / February 20, 2024...

Biofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AG

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Volume	25,769.00
52-Wk High	$13.42
52-Wk Low	$0.61

BFRI Biofrontera Inc

About

Feed

News

Earnings

Fundamentals